Fig. 3

TRQ decreases the activation of NLRP3 in DENV-2 infected BV2 cells. BV2 cells were infected with DENV-2 (0.5 MOI) in the presence or absence of TRQ (1/400, 1/200, 1/100) for 24 h. A, B TRQ downregulates the mRNA expression levels of Nlrp3 (A) and Il1b (B) in DENV-2 infected BV2 cells, as detected by qRT‒PCR. C–F TRQ decreases the protein expression levels of NLRP3 and cleaved caspase-1 in DENV-2 infected BV2 cells. Total proteins and supernatant proteins were extracted, and Western blotting was performed. G TRQ attenuates the release of IL1B in DENV-2 infected BV2 cells. The cell culture media were collected, and ELISA was performed to quantify the concentration of IL1B. H–J The activation of NLRP3 reverses the anti-inflammatory activities of TRQ in DENV-infected BV2 cells. BV2 cells were infected with DENV-2 (0.5 MOI) in the presence or absence of TRQ (1/100) for 22 h and then treated with 10 µM NLRP3 agonist nigericin for 2 h. The levels of IL1B (H) and cleaved CASP1 (I, J) in supernatants were analyzed by ELISA or Western blotting, respectively.^*P<0.05,  ^**P < 0.01, ^***P < 0.001 vs. control group; ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. DENV-2 group. ^$P < 0.05 vs. DENV-2 + TRQ group